financetom
Business
financetom
/
Business
/
Solventum Q1 Adjusted Earnings Fall, Sales Rise; 2025 Outlook Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Solventum Q1 Adjusted Earnings Fall, Sales Rise; 2025 Outlook Reaffirmed
May 26, 2025 4:38 AM

04:36 PM EDT, 05/08/2025 (MT Newswires) -- Solventum ( SOLV ) reported Q1 adjusted diluted earnings late Thursday of $1.34 per share, down from $2.08 a year earlier.

Analysts polled by FactSet expected $1.19.

Net sales for the quarter ended March 31 were $2.07 billion, up from $2.02 billion a year earlier.

Analysts surveyed by FactSet expected $2.02 billion.

The company reaffirmed its full-year 2025 adjusted earnings outlook of $5.45 to $5.65 per share. Analysts polled by FactSet expect $5.54.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
International Paper's Shares Fall After Lower Q1 Adjusted Earnings, Net Sales
International Paper's Shares Fall After Lower Q1 Adjusted Earnings, Net Sales
Apr 25, 2024
09:37 AM EDT, 04/25/2024 (MT Newswires) -- International Paper ( IP ) shares were down 2.7% in early Thursday trading after the company reported Q1 adjusted operating earnings of $0.17 per diluted share, down from $0.53 a year earlier. Analysts polled by Capital IQ expected $0.22. Net sales for the quarter ended March 31 were $4.62 billion, down from $5.02...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Apr 25, 2024
April 25 (Reuters) - GlaxoSmithKline sued Pfizer ( PFE ) and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer ( PFE ) and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed more...
EMCOR Group's Q1 Earnings, Revenue Increase; Raises 2024 Guidance
EMCOR Group's Q1 Earnings, Revenue Increase; Raises 2024 Guidance
Apr 25, 2024
09:31 AM EDT, 04/25/2024 (MT Newswires) -- EMCOR Group ( EME ) reported Q1 earnings Thursday of $4.17 per diluted share, up from $2.32 a year earlier. Analysts polled by Capital IQ expected $2.97. Revenue for the quarter ended March 31 was $3.43 billion, up from $2.89 billion a year earlier. Analysts surveyed by Capital IQ expected $3.23 billion. For...
Pool Q1 Adjusted EPS, Sales Decline, Trail Consensus Views; Guides 2024 Earnings In-Line
Pool Q1 Adjusted EPS, Sales Decline, Trail Consensus Views; Guides 2024 Earnings In-Line
Apr 25, 2024
09:30 AM EDT, 04/25/2024 (MT Newswires) -- Pool Corp. ( POOL ) on Thursday reported Q1 adjusted net income of $1.85 per diluted share, compared with $2.46 a year earlier. Analysts polled by Capital IQ expected $1.93. Revenue for the quarter ended March 31 was $1.12 billion, down from $1.21 billion a year earlier. Analysts expected $1.13 billion. For 2024,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved